Dr. Luke Piggott leads the preclinical and clinical pharmacology programs at Debiopharm. He focuses on leveraging advanced technologies like artificial intelligence to accelerate the development of targeted therapies. He has worked with DNA damage response (DDR) inhibitors and exploring novel-novel drug combinations to address high unmet medical needs.